IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study

Eid, M.; Alset, D.; Timoshkina, N.; Gvaldin, D.; Rostorguev, E.; Kavitskiy, S.; Novikova, I.

Авторы: Eid Moez, Alset Dema, Timoshkina Nataliya, Gvaldin Dmitriy, Rostorguev Eduard, Kavitskiy Sergey, Novikova Inna
Журнал: Journal of the Egyptian National Cancer Institute
Том: 37
Номер: 1
Год издания: 2025
Издательство: National Cancer Institute
Местоположение издательства: Egypt
Первая страница: 1
Последняя страница: 9
Номер статьи: 36
DOI: 10.1186/s43046-025-00296-w
Аннотация: AbstractGlioma is a devastating type of brain tumor with high malignancy, an extremely high mortality rate, and a recur-rence risk. Molecular markers are known to have a major role in classification, prognosis, survival rate, and therapydetermination for different glioma subtypes. The aim of this study was to investigate the association of gliomas’main genetic markers: isocitrate dehydrogenase (IDH) mutations and O6-methylguanine-DNA methyltransferase(MGMT) promoter methylation status with the survival rate in Russian patients with glioblastoma and other glialtumors. According to histological subtype, included glioma patients were divided into two groups: glioblastoma (n=90) and other gliomas (n=40). IDH mutations were screened by high-resolution melting-curve analysis (HRM) followed by direct sequencing, and MGMT methylation was detected with pyrosequencing. Our data showed that IDHmutations are significantly more frequent among patients with other gliomas compared to glioblastoma patients(p < 0.001). Patients with mutated IDH gene have a significantly higher progression-free survival (PFS) and overallsurvival (OS) rates than those with wild-type genes. MGMT promoter methylation status was found to be significantlyassociated with PFS, but not OS. The presence of IDH mutation with a methylated MGMT promoter significantlyincreased patients’ PFS and OS. To our knowledge, this is the first study to investigate the association of IDH and MGMTgenetic biomarkers with glioma in the Russian population. Our findings could be used in future studies to improveglioma prognosis and classification and reach a personalized treatment protocols depending on multiple molecularbiomarkers.Keywords Glioma, IDH, MGMT, Survival rate, Glioblastoma
Добавил в систему: Росторгуев Эдуард Евгеньевич

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ПсковГУ
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ПсковГУ

IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort studyстатья

Прикрепленные файлы